2017
DOI: 10.1016/j.jvir.2016.12.787
|View full text |Cite
|
Sign up to set email alerts
|

Albumin/bilirubin grade (ALBI): a robust predictor of decompensation and poor outcome in high-risk patients undergoing TACE for HCC

Abstract: EDEB-TACE groups was 91.2 days and 153.6 days respectively (p ¼ 0.34). No significant differences between the groups regarding doxorubicin dose, age, sex, BCLC staging, portal vein invasion, liver function (Child-Pugh) or tumor grading. The mean percent tumor necrosis at explant for the DEB-TACE group was 74.7% (range 5-100%, STD 32.3) and for the EDEB-TACE 93% (range 70-100%, STD 11) P ¼ 0.18. There was no significant difference in treatment related liver toxicity. Conclusions: Adding ethiodized oil to existi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In our study, TACE was applied to patients with intermediate or advanced stages of disease. In these patients, albumin is an essential factor for the overall outcome and functions as a surrogate marker of therapy tolerance (42)(43)(44). Thus, the albumin component may be superior and outweigh the nutritional aspect in these patients, which could be underrepresented in the factor weighting in the CONUT score.…”
Section: Discussionmentioning
confidence: 99%
“…In our study, TACE was applied to patients with intermediate or advanced stages of disease. In these patients, albumin is an essential factor for the overall outcome and functions as a surrogate marker of therapy tolerance (42)(43)(44). Thus, the albumin component may be superior and outweigh the nutritional aspect in these patients, which could be underrepresented in the factor weighting in the CONUT score.…”
Section: Discussionmentioning
confidence: 99%